Fennec Pharmaceuticals heads into its third-quarter report with an odd disconnect. Management closed its last call in the most confident tone of the past year, pointing to all-time highs in July for completed infusions, new patient enrollments, active patients and new customers. The stock has gone the other way, falling about 23% since that report and trailing the S&P 500 by more than 17 percentage points. The release, due before the market opens on November 12, should show whether the market has been too skeptical or whether it sensed that the summer surge would be hard to sustain.

The Street is looking for earnings of $0.09 a share on revenue of about $18.9 million. That would mean roughly 52% revenue growth from the $12.5 million posted a year ago and a sharp swing from the $0.02 loss in that period. Measured against last quarter's $17.9 million, though, the forecast implies only about $1 million of sequential growth, a slower step than the climb from the first quarter to the second. Fennec still offers no formal revenue guidance, and management has said only that it may consider an outlook for 2027. With no company range to anchor them, analysts appear to have penciled in a cautious top-line number, while the near doubling of EPS from $0.05 assumes meaningful operating leverage.

That combination is the crux of the quarter. Project Ignite, the sales-force expansion that widened the target prescriber base from about 1,300 to roughly 5,000, drove a 280% jump in sales calls and double-digit sequential demand growth last quarter. Reps hired in early March were still early in their ramp, so this is the first full quarter in which their productivity should show up clearly. A revenue figure well above consensus, backed by continued gains in active patients and affiliated sites, would confirm that July was a sign of momentum rather than a one-month spike. Evidence that the recent community oncology network formulary win is turning into orders would add to the case. A result near or below $18.9 million would suggest the expanded field force is producing activity faster than prescriptions.

Costs are the other swing factor. Operating expenses are heading toward about $50 million for 2026, well above the $33 million to $35 million spent in 2025. Last quarter's record adjusted EBITDA of $2.8 million showed revenue can outpace that spending, but reaching $0.09 on only modestly higher sales leaves little room for expense creep. Management has also flagged that third-quarter cash would decline sequentially because of customer collection timing. A dip was expected, but a larger-than-anticipated drop could unsettle a market already treating the stock warily. Reaffirming that cash will be higher by year-end would help.

Sentiment has warmed noticeably, moving from a bearish reading before the last report to a moderately bullish one now. The chart tells a gloomier story. At $9.39, shares sit just above the post-earnings low of $9.33 and barely clear of the 200-day moving average at $9.25, far below the $13.25 peak reached after the last report. The stock is pressing on support, so the results could decide whether that floor holds.

Updates on the investigator-sponsored trials at City of Hope, Tampa General and the University of Arizona, the Japanese pharmacokinetic data presented at SIOP, partnering talks in Asia and the gynecologic cancer opportunity will add color. They are secondary, however, to one question: whether Fennec's bigger commercial engine is turning record activity into sequential revenue growth fast enough to outrun a much larger cost base. If it is, the recent selloff will look like an overreaction. If it is not, the most upbeat call of the past year will start to look premature.